WCN25-4264 THE DETERMINANTS OF MORTALITY AMONG CHRONIC HEMODIALYSIS PATIENTS

approved for CKD-related anemia by stimulating endogenous erythropoietin production.This study aims to compare the efficacy and safety of Desidustat with ESAs in CKD patients with anemia.Methods: This prospective, observational study was conducted at the Department of Nephrology, Apollo Hospital International Limited, Gandhinagar, from February 1, 2023, to June 30, 2024.A total of 60 patients with CKD-related anemia were enrolled, with 30 patients receiving Desidustat and 30 receiving ESA therapy (epoetin alfa).According to the eligibility criteria patients were enrolled in the study.Hb levels were assessed at baseline, 15 days, and 1, 2, and 3 months after initiating treatment.Data on cost, ease of handling and administration, compliance, and adverse events were also collected.Results: The mean age of participants was 50.5 years and 53.9 years in the Desidustat and ESA groups(p 0.31).Both groups exhibited a significant rise in hemoglobin levels over time.Baseline mean Hb levels were 7.9 g/dL in the Desidustat group and 7.8 g/dL in the ESA group (p 0.47).By the third month, Hb levels increased to 9.3 g/dL in the Desidustat group and 9.1 g/dL in the ESA group (p 0.48), with no statistically significant difference in Hb improvement between the groups.Desidustat was also found to be significantly more cost-effective, with 96.7% of patients finding it feasible compared to 66% in the ESA group (p < 0.01).A higher proportion of Desidustat patients reported ease of administration (96.7% vs. 70%, p < 0.01) and storage (100% vs. 83.3%,p < 0.05).Compliance rates were comparable between groups (80% vs. 73.3%,p 0.54).Adverse events were minimal and comparable in both groups.